干扰素α-2b联合苦参素治疗慢性乙型肝炎的临床研究  

Clinical study of the interferon α-2b combined with kurorinone in the treatment of chronic hepatitis B

作　　者：黄以群[1] 林珍辉[1] 纪树梅[1] 许正锯[1] 王崇国[1] 

机构地区：[1]解放军第180医院南京军区临床肝病中心,福建泉州362000

出　　处：《中华传染病杂志》2004年第4期259-262,共4页Chinese Journal of Infectious Diseases

摘　　要：目的　探讨干扰素α 2b(IFNα 2b)联合苦参素治疗慢性乙型肝炎 (CHB)患者的临床疗效。方法　将 14 6例CHB ,随机分为A、B、C、D 4组。在常规保肝治疗 (D组 )基础上 ,A组加用IFNα 2b联合苦参素治疗 ;B组单用IFNα 2b ;C组单用苦参素 ,疗程 6个月 ,随访 6个月。采用免疫组织化学、放射免疫法及酶联免疫吸附法 ,对治疗前后肝组织学、肝组织转化生长因子 β(TGF β)的表达及血清TGF β、HBeAg、HBVDNA等指标的变化进行了观察。 结果　治疗后A组组织学肝纤维化程度计分、肝组织TGF β的表达及血清TGF β、HBeAg、HBVDNA等指标均显著下降 ,与B、C组比较差异有显著性 (P <0 .0 5或P <0 .0 1) ,肝组织TGF β的表达与肝脏纤维化的动态变化相一致 ;B组与C组相比差异无显著性 (P >0 .0 5 )。结论　IFNα 2b联合苦参素治疗慢性乙型肝炎的疗效优于单一用药。Objective To study the efficacy of interferon α 2b (IFNα 2b) combined with kurorinone in the treatment of chronic hepatitis B. Methods 146 patients with chronic hepatitis B were randomly divided into four groups(A,B,C,D). Based on the similar general treatment(group D),37 patients in group A was treated with IFN α 2b and kurorinone. However, 37 patients in group B and 36 patients in group C received IFN α 2b and kurorinone,respectively.Dynamic changes and relationships among liver histopathology,expression of TGF β in liver tissue and serum levels of TGF β,HBeAg,HBV DNA were studied using immunohistochemistry,radioimmunoassay and ELISA before and after treatment of IFN α 2b and kurorinone. Results The score of histological hepatitic fibrosis,expression of TGF β in liver tissue and serum levels of TGF β,HBeAg, HBV DNA in group A showed significant lower than in group B and group C ( P <0.05 or P <0.01). The expression of TGF β in liver tissue was positively correlated with the staging of fibrotic liver. Group B showed no significant difference compared with group C. Conclusions Superior to IFN α 2b or kurorinone alone, IFN α 2b combined with kurorinone is more effective for treating patients with chronic hepatitis B.

关 键 词：治疗 苦参素 IFNΑ-2B 联合 慢性乙型肝炎 干扰素Α-2B 肝组织 单用 差异 一致 

分 类 号：R512.6[医药卫生—内科学]